{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"99.474","value":"36.445"},{"groupId":"OG001","spread":"117.534","value":"14.003"}]}],"title":"Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.547","value":"0.747"},{"groupId":"OG001","spread":"66.752","value":"0.893"}]}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0","value":"0.717"},{"groupId":"OG001","spread":"78.568","value":"0.869"}]}],"title":"Cycle 1 Day 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.784","value":"0.727"},{"groupId":"OG001","spread":"78.665","value":"0.896"}]}],"title":"Cycle 1 Day 15"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Tisotumab vedotin 0.9 mg/kg was administered as an intravenous infusion, over a minimum of 30 minutes, 3 times every 4 weeks (3q4wk).","id":"OG000","title":"Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg"},{"description":"Tisotumab vedotin 1.2 mg/kg was administered as an intravenous infusion, over a minimum of 30 minutes, 3 times every 4 weeks (3q4wk).","id":"OG001","title":"Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Insufficient samples were taken in Cycle 2 and beyond to calculate PK parameters, therefore only Cycle 1 is reported. Cycle 1 is an overall value, calculated over the entire cycle.","reportingStatus":"POSTED","timeFrame":"Before infusion, end of infusion (+15 minutes), and +2 hours post infusion on days 1, 8, and 15, +24 hours 1st infusion (Day 2), +24 hours 3rd infusion (Day 16), +72 hours 3rd infusion (Day 18), and +168 hours 3rd infusion (Day 22) of Cycle 1","title":"Part 1: Tmax: Time to Reach the Maximum Plasma Concentration for Total HuMax-TF (Conjugated and Non-conjugated)","type":"SECONDARY","unitOfMeasure":"hours"}